Instem Enters Early Phase Clinical Market
News May 14, 2013
Logos is headquartered in London with staff located both in the United Kingdom and the United States, Logos is well known for providing its customers with quality products that are developed following GCP regulatory requirements along with high caliber subject matter experts to help streamline clinical trials and reduce drug development time.
The ALPHADAS® software solution suite is a proactive eSource clinical trials system that is mobile, schedule-driven, and provides real-time bedside or station based direct data capture that virtually eliminates paper-based data. ALPHADAS delivers enhanced quality, operational efficiencies and time savings across the clinic, data management, recruitment, site administration and the laboratory.
“Instem has a fantastic reputation in the pharmaceutical industry for innovative and quality software solutions backed by outstanding customer support,” comments Giles Wilson, CEO & founder of Logos Technologies. “The majority of our new business has come from a reputation of successful delivery of market leading products and services. Instem’s proven track record in client satisfaction along with their likeminded values was a key reason to our joining forces, as it supports our overall vision of delighting each and every client. Being part of the Instem group provides us with even greater confidence and the financial backing needed to compete at a new level as we look to accelerate our leadership position in the clinical space while being part of the larger mission to deliver data-driven insights.”
As part of their mission to deliver compelling solutions for data collection, management and analysis across the R&D continuum, Instem’s entry into the early clinical market provides greater access to early phase clinical data in both healthy and patient populations, advancing Instem’s translational informatics technology strategy.
Phil Reason, President & CEO of Instem commented, “We are delighted that the talented team at Logos will be joining the Instem group and we look forward to working together to provide valuable automation tools that will enable our clients to bring new products to market quickly and cost effectively. The ALPHADAS suite is an acknowledged leader in the early phase e-source data capture industry and the integration of the business also expands our product portfolio reach and provides avenues for extending our Provantis® and Centrus™ solutions.”
Having become the standard by which organizations across four continents accelerate and streamline clinical trial operations and service, Instem is planning a series of presentations and promotional programs to further demonstrate the value of ALPHADAS as part of the larger Instem organization.
One of the value-added offerings this acquisition will bring is the introduction of a Software-as-a-Service (SaaS) version of ALPHADAS, which will be especially useful for the many small clinical units within the early phase market. Instem’s SaaS model offers simpler, more cost effective ways to provide software functionality, maintenance, and support over the Internet.
ALPHADAS is believed to have been selected for the majority of new business placed in the early phase market in the last three years, delivering both the innovation and performance required by today’s clinical R&D units. ALPHADAS was most recently chosen by SNBL for its clinical pharmacology unit in Baltimore, Maryland.
The Powerful ALPHADAS system will enhance Instem’s Study Workflow and Automation Suite that includes solutions enabling organizations of all sizes to collect, manage, review and submit study data that streamline processes, increase quality and enhance development programs.
Society relies on networks connected to other networks at scales. Understanding how connected networks behave and how breakdowns can be identified, prevented or repaired involves mathematics, engineering and physics. In a new paper, researchers show how complicated and surprising behavior can emerge in a very simple experimental network.